Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-524 (Motavizumab) Dose-Escalation in High-Risk Children
NCT00192478Phase 2Completed
- Sponsor
- MedImmune
- Start
- Feb 2004
- Primary completion
- May 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of motavizumab in respiratory syncytial virus infection (RSV), sponsored by MedImmune. Primary endpoints: Safety and tolerability of repeated IM doses of MEDI-524 and Pharmacokinetics of MEDI-524. Started Feb 2004; status: completed.
02
Drugs
motavizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00192478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00192478.